Study confirms that intracoronary and intravenous use of abciximab during angioplasty yield similar results
A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV). The results of the AIDA STEMI MRI sub-study were presented today the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
The AIDA STEMI trial was a randomized, open-label, multicenter trial in 2,065 patients presenting with ST-elevation myocardial infarction (STEMI) comparing intracoronary (IC) versus intravenous (IV) abciximab during PCI with subsequent 12 hour intravenous infusion. Last year, researchers reported that the trial found that both methods yielded similar 90-day rates of all-cause mortality, recurrent heart attack or congestive heart failure.
Researchers enrolled 703 patients within the overall trial in a cardiac magnetic resonance imaging sub-study, one of the largest MRI sub-studies conducted in patients with STEMI. Cardiac MRI allows for a more sensitive investigation of the mechanistic and pathophysiological effects of STEMI therapies on myocardial damage and reperfusion injury.
Cardiac MRI was completed within four days after heart attack using a standardized protocol including edema imaging and late gadolinium enhancement. Researchers examined infarct size, myocardial salvage, microvascular obstruction and ventricular function to determine the potential benefits of intracoronary compared to intravenous application of abciximab.
The amount of myocardium at risk and final infarct size did not differ significantly between the IC versus the IV abciximab groups. Consequently, the myocardial salvage index was similar between the two groups. In further detailed analysis there were no differences in microvascular obstruction between both treatment groups.
"Results of this sub-study demonstrate that intracoronary as compared to intravenous abciximab did not result in a difference in myocardial damage or reperfusion injury," said lead investigator Holger Thiele, MD. Dr. Thiele is Co-Director of the University of Leipzig - Heart Center in Germany.
"These findings confirm similarities in the combined endpoint of death, reinfarction and congestive heart failure found between the two methods in the AIDA STEMI trial," Dr. Thiele said.
Dr. Thiele will present the AIDA STEMI MRI sub-study on Thursday October 25 at 12:30 PM EST in the Main Arena (Hall D) at the Miami Beach Convention Center.
Provided by Cardiovascular Research Foundation
- Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack Mar 25, 2012 | not rated yet | 0
- Study examines outcomes of erythropoietin use for heart attack patients undergoing PCI May 10, 2011 | not rated yet | 0
- Comparison of anticoagulants for angioplasty show similar outcomes Mar 30, 2008 | not rated yet | 0
- Intra-aortic balloon pumps do not reduce infarct size in patients with STEMI without cardiac shock Aug 30, 2011 | not rated yet | 0
- Long-term outcome similar with thrombus aspiration and stents in PCI May 02, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Question of reflection and transmission of TEM wave in normal incidenc
1 hour ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
2 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
3 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
9 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
Calculating on-axis elements of a solenoid
21 hours ago I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
latitude & longitude & air pressure
22 hours ago Hi there, I have a peculiar question. Imagine that you are in a earth position, obtained by google, that gives you the latitude and longitude....
- More from Physics Forums - Classical Physics
More news stories
UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden ...
Cardiology 2 hours ago | not rated yet | 0
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
Cardiology 6 hours ago | not rated yet | 0
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology May 22, 2013 | not rated yet | 0
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology May 22, 2013 | not rated yet | 0
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology May 22, 2013 | 5 / 5 (1) | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
25 minutes ago | not rated yet | 0 |
Two out of five medical students have an unconscious bias against obese people, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published online ahead of print in the Journal of ...
7 seconds ago | not rated yet | 0
International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...
6 seconds ago | not rated yet | 0
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
36 minutes ago | not rated yet | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
39 minutes ago | not rated yet | 0
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
40 minutes ago | not rated yet | 0